Anti-HIV Nanotherapeutics and their Challenges in the Future

Preview this chapter:

Anti-HIV Nanotherapeutics and their Challenges in the Future, Page 1 of 1

< Previous page | Next page > /docserver/preview/fulltext/9789815256505/chapter-6-1.gif

The human immunodeficiency virus (HIV) affects the body's immune system of the body in such a way that a minor infection, such as a cold, can become severe. The treatment of HIV is challenging due to the virus's resistance. A high dose of the drug is required to achieve viral load reduction. Current available antiretroviral therapy can improve the health of HIV patients, although systemic viral load may remain sequestered if the virus persists in anatomically privileged areas of the body. Nanotechnology-based drug delivery techniques are being developed to target the virus in various tissue compartments. Due to their durability, safety, multimodality, and multifunctionality, nanomaterials are extensively used in biological applications. However, unwanted interactions with plasma proteins in the systemic circulation, failure to cross biological barriers, and nonspecific distribution throughout the body are challenges. It is required to mitigate these challenges in the field of nanomedicine in the near future. So, the main objective of this chapter is to compile information on pathogenesis and their targets, as well as how anti-retroviral drugs improve efficacy in treatment. This chapter will provide new insight intofinding nanotherapeutics for HIV.